bluebird bio Inc (BLUE) Stake Lowered by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. trimmed its position in shares of bluebird bio Inc (NASDAQ:BLUE) by 50.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,444 shares of the biotechnology company’s stock after selling 10,819 shares during the period. Daiwa Securities Group Inc.’s holdings in bluebird bio were worth $1,860,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of BLUE. Ark Investment Management LLC raised its stake in shares of bluebird bio by 44.8% during the second quarter. Ark Investment Management LLC now owns 119,683 shares of the biotechnology company’s stock valued at $12,573,000 after acquiring an additional 37,021 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of bluebird bio by 25.0% during the second quarter. Dimensional Fund Advisors LP now owns 106,189 shares of the biotechnology company’s stock valued at $11,158,000 after acquiring an additional 21,228 shares during the last quarter. QS Investors LLC raised its stake in shares of bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 500 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of bluebird bio during the second quarter valued at about $5,252,000. Finally, Cornerstone Capital Management Holdings LLC. raised its stake in shares of bluebird bio by 0.8% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock valued at $1,885,000 after acquiring an additional 140 shares during the last quarter.

BLUE has been the subject of several recent analyst reports. Leerink Swann reaffirmed an “outperform” rating and set a $162.00 price objective (up from $145.00) on shares of bluebird bio in a research note on Wednesday, November 1st. BMO Capital Markets upped their price objective on shares of bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, October 30th. SunTrust Banks upped their price objective on shares of bluebird bio from $108.00 to $163.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Jefferies Group raised shares of bluebird bio from a “hold” rating to a “buy” rating and upped their price objective for the company from $130.00 to $211.00 in a research note on Monday, December 11th. Finally, Barclays reaffirmed an “overweight” rating and set a $209.00 price objective (up from $162.00) on shares of bluebird bio in a research note on Wednesday, December 13th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $161.45.

bluebird bio Inc (NASDAQ:BLUE) opened at $207.25 on Thursday. bluebird bio Inc has a one year low of $73.95 and a one year high of $222.03. The stock has a market cap of $9,786.05, a PE ratio of -29.52 and a beta of 2.07.

In other bluebird bio news, insider David Davidson sold 4,000 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $202.36, for a total value of $809,440.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jason Cole sold 25,000 shares of the company’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $195.91, for a total transaction of $4,897,750.00. Following the completion of the sale, the insider now owns 44,798 shares in the company, valued at approximately $8,776,376.18. The disclosure for this sale can be found here. Over the last three months, insiders sold 200,280 shares of company stock valued at $37,818,846. 3.90% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/02/15/bluebird-bio-inc-blue-stake-lowered-by-daiwa-securities-group-inc.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply